Processa Pharmaceuticals Inc. (PCSA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

PCSA scores 39 out of 100 and receives a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:

• Fundamental cash engine: 7 / 20. The pillar notes ROIC of -35% and an FCF yield of 0%. For a prospective investor, this indicates the business is not currently generating returns on invested capital or free cash flow to offset its reported losses.
• Whale 13F flow: 8 / 20. The pillar summarizes institutional accumulation and options positioning.
• Insider conviction: 5 / 20. The lowest pillar, covering SEC Form 4 and Congressional PTR cluster flow. A low score signals weak insider-level conviction signals in the rating's inputs.
• Macro regime fit: 9 / 20. The pillar cites beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is modeled to move in line with the broader market, offering no defensive cushion.
• Forensic balance sheet: 10 / 20. The pillar references Altman Z of 2.5, Piotroski F of 2/9, and Debt/Equity of 0.5. These metrics sit in the middle-to-weak range and point to a balance sheet that warrants close monitoring.

Taken together, the rating frames PCSA as a high-risk, cash-consuming equity where the upside case depends on events outside the current financial profile. Valuation tradeoffs are significant: with a market capitalization of $5. Upside drivers would need to come from pipeline progress and corporate actions rather than current operations.

Processa Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations. The market capitalization is listed as $0.0B. Reported revenue was — in each of FY 2023, FY 2024, and FY 2025, indicating no reported revenue in the periods provided.

The company reported operating losses and net losses in each period shown, with gross, operating, and net margins all listed at 0% in market data. ROIC is -35%. The Altman Z-Score of 2.5 and Piotroski F-Score of 2/9 are cited within the forensic balance sheet pillar; the Piotroski score is weak. Debt/Equity is listed as 0.5. Reported cash rose from $1.2M (FY 2024) to $5.5M (FY 2025), while FCF remained negative in every period.

• 🐂 Primary Bull Case: A green-flagged FDA IND clearance for VT-7208 in urticaria, paired with a Generian partnership, offers a pipeline catalyst that could support the stock independent of current financials. With Fundamental Cash Engine at 7/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 8/20, sustained execution supports upside toward the top of the $1.04 – $10.25 52-week range.
• 🐻 Primary Bear Case: Negative operating income in every reported period, a -35% ROIC, and a 2/9 Piotroski F-Score point to a cash-consuming balance sheet. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

An investor should note that the pipeline (VT-7208) and the Vidya merger are the company's main external linkages per the news wire, but their supply-chain relationships are not mapped in the provided graph.

• Key Question #1: What is the company's revenue model and does it expect any product revenue, given — reported in each period?
• Key Question #2: What are the terms, share count impact, and timing of the proposed reverse stock split and the Vidya Therapeutics merger?
• Key Question #3: What is the current cash runway relative to the FY 2025 FCF of -$11.4M, and how will the company fund operations?